195 related articles for article (PubMed ID: 9332462)
21. The Charing Cross Hospital experience with temozolomide in patients with gliomas.
Newlands ES; O'Reilly SM; Glaser MG; Bower M; Evans H; Brock C; Brampton MH; Colquhoun I; Lewis P; Rice-Edwards JM; Illingworth RD; Richards PG
Eur J Cancer; 1996 Dec; 32A(13):2236-41. PubMed ID: 9038604
[TBL] [Abstract][Full Text] [Related]
22. Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
Chan DT; Poon WS; Chan YL; Ng HK
Hong Kong Med J; 2005 Dec; 11(6):452-6. PubMed ID: 16340021
[TBL] [Abstract][Full Text] [Related]
23. An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
Harris MT; Rosenthal MA; Ashley DL; Cher L
J Clin Neurosci; 2001 Jul; 8(4):325-7. PubMed ID: 11437571
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Omuro A; Chan TA; Abrey LE; Khasraw M; Reiner AS; Kaley TJ; Deangelis LM; Lassman AB; Nolan CP; Gavrilovic IT; Hormigo A; Salvant C; Heguy A; Kaufman A; Huse JT; Panageas KS; Hottinger AF; Mellinghoff I
Neuro Oncol; 2013 Feb; 15(2):242-50. PubMed ID: 23243055
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status.
Janinis J; Efstathiou E; Panopoulos C; Samantas E; Aravantinos G; Christodoulou C; Skarlos D
Med Oncol; 2000 May; 17(2):106-10. PubMed ID: 10871815
[TBL] [Abstract][Full Text] [Related]
26. [Prescription guidebook for temozolomide usage in brain tumors].
Tilleul P; Brignone M; Hassani Y; Taillandier L; Taillibert S; Cartalat-Carel S; Borget I; Chinot O
Bull Cancer; 2009 May; 96(5):579-89. PubMed ID: 19467988
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
Brada M; Viviers L; Abson C; Hines F; Britton J; Ashley S; Sardell S; Traish D; Gonsalves A; Wilkins P; Westbury C
Ann Oncol; 2003 Dec; 14(12):1715-21. PubMed ID: 14630674
[TBL] [Abstract][Full Text] [Related]
28. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas.
Brock CS; Young H; O'Reilly SM; Matthews J; Osman S; Evans H; Newlands ES; Price PM
Br J Cancer; 2000 Feb; 82(3):608-15. PubMed ID: 10682673
[TBL] [Abstract][Full Text] [Related]
29. Dynamic history of low-grade gliomas before and after temozolomide treatment.
Ricard D; Kaloshi G; Amiel-Benouaich A; Lejeune J; Marie Y; Mandonnet E; Kujas M; Mokhtari K; Taillibert S; Laigle-Donadey F; Carpentier AF; Omuro A; Capelle L; Duffau H; Cornu P; Guillevin R; Sanson M; Hoang-Xuan K; Delattre JY
Ann Neurol; 2007 May; 61(5):484-90. PubMed ID: 17469128
[TBL] [Abstract][Full Text] [Related]
30. BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Rosenthal MA; Ashley DL; Cher L
J Clin Neurosci; 2004 May; 11(4):374-5. PubMed ID: 15080950
[TBL] [Abstract][Full Text] [Related]
31. Extended-schedule dose-dense temozolomide in refractory gliomas.
Berrocal A; Perez Segura P; Gil M; Balaña C; Garcia Lopez J; Yaya R; Rodríguez J; Reynes G; Gallego O; Iglesias L;
J Neurooncol; 2010 Feb; 96(3):417-22. PubMed ID: 19669096
[TBL] [Abstract][Full Text] [Related]
32. Temozolomide treatment in glioma--experiences in two university hospitals in Finland.
Mäenpää HO; Aaltonen K; Mäntylä R; Minn H
Acta Oncol; 2004; 43(6):579-84. PubMed ID: 15370616
[TBL] [Abstract][Full Text] [Related]
33. Temozolomide as first-line agent in treating high-grade gliomas: phase II study.
Chibbaro S; Benvenuti L; Caprio A; Carnesecchi S; Pulerà F; Faggionato F; Serino D; Galli C; Andreuccetti M; Buxton N; Gagliardi R
J Neurooncol; 2004; 67(1-2):77-81. PubMed ID: 15072451
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide.
Brada M; Ashley S; Dowe A; Gonsalves A; Huchet A; Pesce G; Reni M; Saran F; Wharram B; Wilkins M; Wilkins P
Ann Oncol; 2005 Jun; 16(6):942-9. PubMed ID: 15870090
[TBL] [Abstract][Full Text] [Related]
35. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas.
Sherman JH; Moldovan K; Yeoh HK; Starke RM; Pouratian N; Shaffrey ME; Schiff D
J Neurosurg; 2011 Jun; 114(6):1617-21. PubMed ID: 21235313
[TBL] [Abstract][Full Text] [Related]
36. Promises and controversies in the management of low-grade glioma.
Stupp R; Baumert BG
Ann Oncol; 2003 Dec; 14(12):1695-6. PubMed ID: 14630671
[No Abstract] [Full Text] [Related]
37. Current and future developments in the use of temozolomide for the treatment of brain tumours.
Stupp R; Gander M; Leyvraz S; Newlands E
Lancet Oncol; 2001 Sep; 2(9):552-60. PubMed ID: 11905710
[TBL] [Abstract][Full Text] [Related]
38. The use of temozolomide in recurrent malignant gliomas.
Gaya A; Rees J; Greenstein A; Stebbing J
Cancer Treat Rev; 2002 Apr; 28(2):115-20. PubMed ID: 12297119
[TBL] [Abstract][Full Text] [Related]
39. Effects of temozolomide in malignant brain tumours.
Osoba D
Lancet; 2000 Jul; 356(9226):342. PubMed ID: 11071219
[No Abstract] [Full Text] [Related]
40. Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
Friedman HS
Semin Oncol; 2000 Jun; 27(3 Suppl 6):35-40. PubMed ID: 10866348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
